Market Overview

Argus Sees Perrigo Going Lower After CEO Exit, Guidance Cut

Argus Sees Perrigo Going Lower After CEO Exit, Guidance Cut
Related PRGO
Digesting Delivering Alpha 2017: The Top Picks You Need To Know
Benzinga's Top Upgrades, Downgrades For September 7, 2017

Perrigo Company plc Ordinary Shares (NYSE: PRGO) shares have come under significant pressure after CEO Papa stepped down and the company reduced its guidance. Argus’ Jacob Kilstein downgraded the rating for Perrigo to Hold, citing the “resulting uncertainty over the company’s strategy.”

Challenges Faced

CEO Papa had put up a massive fight to ward off a takeover by Mylan NV (NASDAQ: MYL). The CEO had indicated that the offer price of $26 billion was too low. Kilstein pointed out, however, that the company was now valued at $14 billion, following the recent pullback. “In hindsight, we feel the deal rejection was a mistake.”

Perrigo recently announced a 13 percent reduction in its earnings guidance. This, and the CEO’s exit, caused the shares to plummet. Moreover, the acquisition of Omega resulted in two quarters of heavy impairment and poor results, Kilstein noted. He mentioned that additional headwinds came in the form of pricing pressures in generics and competition in specialty medicines.

Discount Warranted

“Perrigo has a leading position in private-label over-the-counter (OTC) pharmaceuticals, which are rapidly taking market share from brand-name OTC products,” Kilstein wrote. He added that the company was expanding into Europe. Despite these positives, the shares were trading at the low end of their historical range and below the peer average. The analyst believes this discount is warranted, given Perrigo weak outlook.

Latest Ratings for PRGO

Sep 2017Canaccord GenuityMaintainsBuy
Sep 2017OppenheimerInitiates Coverage OnOutperform
Aug 2017Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Argus Jacob KilsteinAnalyst Color Downgrades Analyst Ratings Best of Benzinga


Related Articles (MYL + PRGO)

View Comments and Join the Discussion!